258 related articles for article (PubMed ID: 9552027)
21. Long-term follow-up of a phase III study of three versus four cycles of bleomycin, etoposide, and cisplatin in favorable-prognosis germ-cell tumors: the Indian University experience.
Saxman SB; Finch D; Gonin R; Einhorn LH
J Clin Oncol; 1998 Feb; 16(2):702-6. PubMed ID: 9469360
[TBL] [Abstract][Full Text] [Related]
22. Sequential intermediate high-dose therapy with etoposide, ifosfamide and cisplatin for patients with germ cell tumors.
Mardiak J; Fuchsberger P; Lakota J; Sálek T; Sycová-Milá Z; Drahokoupilová M; Baláz M; Koza I
Neoplasma; 2000; 47(4):239-43. PubMed ID: 11043829
[TBL] [Abstract][Full Text] [Related]
23. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
24. A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group.
Kosmidis P; Mylonakis N; Fountzilas G; Pavlidis N; Samantas E; Karabelis A; Kattis K; Skarlos D
Ann Oncol; 1996 Jul; 7(5):517-20. PubMed ID: 8839908
[TBL] [Abstract][Full Text] [Related]
25. Ifosfamide in germ cell tumors.
Einhorn LH
Oncology; 2003; 65 Suppl 2():73-5. PubMed ID: 14586153
[TBL] [Abstract][Full Text] [Related]
26. First-line high-dose chemotherapy compared with standard-dose PEB/VIP chemotherapy in patients with advanced germ cell tumors: A multivariate and matched-pair analysis.
Bokemeyer C; Kollmannsberger C; Meisner C; Harstrick A; Beyer J; Metzner B; Hartmann JT; Schmoll HJ; Einhorn L; Kanz L; Nichols C
J Clin Oncol; 1999 Nov; 17(11):3450-6. PubMed ID: 10550141
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of cisplatin, vinblastine, and bleomycin versus vinblastine, cisplatin, and etoposide in the treatment of advanced germ cell tumors of the testis: a Southwest Oncology Group study.
Wozniak AJ; Samson MK; Shah NT; Crawford ED; Ford CD; Altman SJ; Stephens RL; Natale RB; Bouroncle BA; Blumenstein BA
J Clin Oncol; 1991 Jan; 9(1):70-6. PubMed ID: 1702148
[TBL] [Abstract][Full Text] [Related]
28. Management of intermediate-prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP.
de Wit R; Louwerens M; de Mulder PH; Verweij J; Rodenhuis S; Schornagel J
Int J Cancer; 1999 Dec; 83(6):831-3. PubMed ID: 10597204
[TBL] [Abstract][Full Text] [Related]
29. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
[TBL] [Abstract][Full Text] [Related]
30. Treatment in germ cell tumours: state of the art.
Tjan-Heijnen VC; Oosterhof GO; de Wit R; De Mulder PH
Eur J Surg Oncol; 1997 Apr; 23(2):110-7. PubMed ID: 9158183
[TBL] [Abstract][Full Text] [Related]
31. Complete response to paclitaxel, ifosfamide, and cisplatin therapy in a case of ovarian ependymoma.
Hino M; Kobayashi Y; Wada M; Hattori Y; Kurahasi T; Nakagawa H
J Obstet Gynaecol Res; 2016 Nov; 42(11):1613-1617. PubMed ID: 27785897
[TBL] [Abstract][Full Text] [Related]
32. Paclitaxel+BEP (T-BEP) regimen as induction chemotherapy in poor prognosis patients with nonseminomatous germ cell tumors: a phase II study.
Tryakin A; Fedyanin M; Kanagavel D; Fainstein I; Sergeev J; Polockij B; Matveev V; Zakharova T; Garin A; Tjulandin S
Urology; 2011 Sep; 78(3):620-5. PubMed ID: 21764427
[TBL] [Abstract][Full Text] [Related]
33. A randomised phase 2 trial of intensive induction chemotherapy (CBOP/BEP) and standard BEP in poor-prognosis germ cell tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604).
Huddart RA; Gabe R; Cafferty FH; Pollock P; White JD; Shamash J; Cullen MH; Stenning SP; ;
Eur Urol; 2015 Mar; 67(3):534-43. PubMed ID: 25001888
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy of disseminated germ cell tumors.
Nichols CR
World J Urol; 2001 Apr; 19(2):82-9. PubMed ID: 11374322
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of advanced testicular cancer and toxicity of chemotherapy].
Kawakita M; Matsuda T; Terachi T; Yoshida O
Hinyokika Kiyo; 1999 Nov; 45(11):783-6. PubMed ID: 10637744
[TBL] [Abstract][Full Text] [Related]
36. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
37. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
[TBL] [Abstract][Full Text] [Related]
38. Antitumoral activity of oxaliplatin/cisplatin-based combination therapy in cisplatin-refractory germ cell cancer patients.
Soulié P; Garrino C; Bensmaïne MA; Bekradda M; Brain E; Di Palma M; Goupil A; Misset JL; Cvitkovic E
J Cancer Res Clin Oncol; 1999 Dec; 125(12):707-11. PubMed ID: 10592105
[TBL] [Abstract][Full Text] [Related]
39. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.
Saxman SB; Nichols CR; Einhorn LH
Chest; 1997 Mar; 111(3):657-60. PubMed ID: 9118704
[TBL] [Abstract][Full Text] [Related]
40. First-line combination chemotherapy with cisplatin, etoposide and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era.
Tanaka H; Yuasa T; Fujii Y; Sakura M; Urakami S; Yamamoto S; Masuda H; Fukui I; Yonese J
Chemotherapy; 2013; 59(6):441-6. PubMed ID: 25060582
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
